Erythropoietin Protein (Human EPO)

Description

Human Erythropoietin Protein (EPO)

References

• Erythropoietin Does Not Alter Serum Profiles of Neuronal and Axonal Biomarkers After Traumatic Brain Injury: Findings From the Australian EPO-TBI Clinical Trial.  Hellewell SC, Mondello S, Conquest A, Shaw G, Madorsky I, Deng JV, Little L, Kobeissy F, Bye N, Bellomo R, Cooper DJ, Vallance S, Board J, Morganti-Kossmann MC. Crit Care Med. 2018 Apr;46(4):554-561.
• Roxadustat (FG-4592) Versus EpoetinAlfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB. Am J Kidney Dis. 2016 Jun;67(6):912-24.
• A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, Gercheva-Kyuchukova L, Anagnostopoulos A, Oliva EN, Symeonidis A, Berger MH, Götze KS, Potamianou A, Haralampiev H, Wapenaar R, Milionis I, Platzbecker U. Leukemia. 2018 Dec;32(12):2648-2658.
• Structure-Function Relationships for Recombinant Erythropoietins: A Case Study From a Proposed Manufacturing Change With Implications for Erythropoietin Biosimilar Study Designs. Grampp G, McElroy PL, Camblin G, Pollock A. J Pharm Sci. 2018 Jun;107(6):1512-1520.
• Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients. Azmandian J, Abbasi MR, Pourfarziani V, Nasiri AA, Ossareh S, Ezzatzadegan Jahromi S, Sanadgol H, Amini S, Shahvaroughi Farahani A. Am J Nephrol. 2018;48(4):251-259.